PARP Pioneer Ashworth Joins Leapfrog Bio in Next-Gen Cancer Fight

SOUTH SAN FRANCISCO, Calif. – March 24, 2026 – In a move signaling significant confidence in a new frontier of cancer therapy, clinical-stage oncology company Leapfrog Bio today announced that Dr. Alan Ashworth, a towering figure in cancer research, will chair its Scientific Advisory Board. Dr. Ashworth is globally renowned for his foundational work that led to PARP inhibitors, a class of drugs that transformed treatment for patients with BRCA-mutated cancers. His decision to guide a seed-funded startup underscores the immense potential of Leapfrog's approach to tackling a new, broad set of genetic vulnerabilities in cancer.

The Architect of Synthetic Lethality

Dr. Alan Ashworth’s career is defined by the translation of profound biological insight into life-saving therapies. His influence on modern oncology cannot be overstated. In 1995, he was a key member of the team that discovered the BRCA2 gene, a critical tumor suppressor. A decade later, in 2005, his lab published a landmark paper demonstrating the concept of "synthetic lethality"—the idea that while healthy cells can survive the loss of one DNA repair gene, cancer cells with a pre-existing mutation (like in BRCA1 or BRCA2) are lethally vulnerable when a second, compensating pathway is blocked by a drug.

This discovery provided the scientific rationale for PARP inhibitors. His work directly guided the clinical development of olaparib, the first genetically targeted PARP inhibitor approved by the FDA. The drug's success validated synthetic lethality as a powerful therapeutic strategy and created a new paradigm in precision medicine.

Today, Dr. Ashworth's influence extends across academia and industry. He serves as President of the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF), and is a co-founder of multiple biotech companies, including Tango Therapeutics, which also focuses on synthetic lethality. His appointment is not merely a title; it is an active endorsement from one of the field's most respected and forward-thinking leaders.

A Strategic Leap for a Seed-Stage Contender

For a young company like Leapfrog Bio, attracting a luminary of Dr. Ashworth's stature is a pivotal event that resonates beyond the lab. The company, currently backed by seed funding from venture firm Two Bear Capital, operates in the high-risk, high-reward world of biotech startups. This appointment serves as a powerful validation of its scientific platform and pipeline, effectively de-risking the venture for future partners and investors.

Two Bear Capital, founded by 20-year Sequoia Capital veteran Michael Goguen, focuses on science-driven companies tackling critical health problems. Its investment in Leapfrog highlights a strategy of backing foundational technology with the potential for massive impact. Dr. Ashworth's involvement amplifies this strategy, providing a level of scientific credibility and strategic guidance that can significantly accelerate a startup's trajectory.

"We’re thrilled to welcome Dr. Ashworth to our Scientific Advisory Board," said Tomas Babak, Ph.D., Founder and Chief Scientific Officer of Leapfrog Bio. "Few scientists have shaped the clinical application of synthetic lethality as profoundly or demonstrated such a clear understanding of what it takes to translate biology into patient benefit."

This move strategically positions Leapfrog Bio as a serious contender in the competitive precision oncology landscape. While large pharmaceutical companies and other biotechs are exploring synthetic lethality, Dr. Ashworth’s direct involvement provides a unique competitive edge and a direct link to the strategy's original success story.

Beyond BRCA: Unlocking New Cancer Vulnerabilities

Leapfrog Bio's mission is to replicate the success of PARP inhibitors for a much broader patient population. The company focuses on cancers driven by loss-of-function (LOF) mutations, which account for roughly two-thirds of all cancers but often lack targeted therapies.

The company's proprietary OncoSLX platform is central to this mission. Unlike traditional screening methods that use genetic tools to simulate a drug's effect, Leapfrog's pharmacogenetic approach screens libraries of actual small-molecule drugs against cancer models. This method is designed to more accurately predict how a drug will behave in a clinical setting, identifying potent drug-gene pairings that might otherwise be missed.

The platform has already yielded promising candidates. The lead program, LFB190, is a BET inhibitor targeting solid tumors with LOF mutations in the EP300 gene. These mutations are found in a significant number of patients across several difficult-to-treat cancers, including approximately 15% of bladder cancers and 6% of non-small cell lung cancers, representing over 60,000 new patients annually in the U.S. alone. Leapfrog is preparing to initiate a Phase 1b/2a clinical trial for LFB190 in mid-2026.

The parallel to Dr. Ashworth's pioneering work is not lost on him. "What excites me about Leapfrog Bio is the clear parallel between our early PARP work and what the company has uncovered with BET inhibition in EP300 loss-of-function–driven cancers," Dr. Ashworth stated. "With two highly compelling programs and a platform capable of generating many more, this is an exciting opportunity."

The company's pipeline also includes LFB083, a candidate targeting cancers with PIK3CA mutations, demonstrating the platform's potential to generate multiple therapies. By focusing on retargeting clinical-stage molecules with established safety profiles, Leapfrog aims to compress development timelines and bring new precision medicines to patients faster. This collaboration between a seasoned pioneer and an innovative company could unlock the next wave of genetically targeted cancer treatments, offering new hope to patients with few options.